Ana Aranda

Ana Aranda

Auto-generated profile, based on publicly available information

Ana Aranda

Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Spain

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2001 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
AAAna Aranda
Ana Aranda
APAngel Pascual
Angel Pascual
The nuclear hormone receptor superfamily includes receptors for thyroid and steroid hormones, retinoids and vitamin D, as well as different “orphan” receptors of unknown ligand. Ligands for some of these receptors have been recently identified, showing that products of lipid metabolism such as fatty acids, prostaglandins, or cholesterol derivatives can regulate gene expression by binding to nuclear receptors. Nuclear receptors act as ligand-inducible transcription factors by directly interacting as monomers, homodimers, or heterodimers with the retinoid X receptor with DNA response elements of target genes, as well as by “cross-talking” to other signaling pathways. The effects of nuclear receptors on transcription are mediated through recruitment of coregulators. A subset of receptors binds corepressor factors and actively represses target gene expression in the absence of ligand. Corepressors are found within multicomponent complexes that contain histone deacetylase activity. Deacetylation leads to chromatin compactation and transcriptional repression. Upon ligand binding, the receptors undergo a conformational change that allows the recruitment of multiple coactivator complexes. Some of these proteins are chromatin remodeling factors or possess histone acetylase activity, whereas others may interact directly with the basic transcriptional machinery. Recruitment of coactivator complexes to the target promoter causes chromatin decompactation and transcriptional activation. The characterization of corepressor and coactivator complexes, in concert with the identification of the specific interaction motifs in the receptors, has demonstrated the existence of a general molecular mechanism by which different receptors elicit their transcriptional responses in target genes.

1 March 2006 in Molecular Cell
Verified
Journal Article
Closed access
SSSalimuddin Shah
Salimuddin Shah
NINaimul Islam
Naimul Islam
Sivanesan DakshanamurthySivanesan Dakshanamurthy
Sivanesan Dakshanamurthy
IRImran Rizvi
Imran Rizvi
MRMahadev Rao
Mahadev Rao
SBStephen W. Byers
Stephen W. Byers

1 July 2013 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
APAngel Pascual
Angel Pascual
AAAna Aranda
Ana Aranda

1 May 1989 in Nature
Verified
Journal Article
Closed access
PBPEDECIBA - Biología
PEDECIBA - Biología
PSPIlar Santisteban
PIlar Santisteban
AAAna Aranda
Ana Aranda

1 December 2004 in Molecular Biology of the Cell
Verified
Journal Article
Open access
PDF file
ECEstela Cañón
Estela Cañón
JCJose Miguel Cosgaya
Jose Miguel Cosgaya
SSSona Scsucova
Sona Scsucova
AAAna Aranda
Ana Aranda
Retinoic acid (RA) is a potent regulator of neuronal cell differentiation. RA normally activates gene expression by binding to nuclear receptors that interact with response elements (RAREs) in regulatory regions of target genes. We show here that in PC12 cell subclones in which the retinoid causes neurite extension, RA induces a rapid and sustained phosphorylation of CREB (cyclic AMP response element binding protein), compatible with a nongenomic effect. RA also causes a rapid increase of CREB phosphorylation in primary cultures of cerebrocortical cells and of dorsal root ganglia neurons from rat embryos. RA-mediated phosphorylation of CREB leads to a direct stimulation of CREB-dependent transcriptional activity and to activation of the expression of genes such as c-fos, which do not contain RAREs but contain cAMP response elements (CREs) in their promoters. CREB is a major target of extracellular signal regulated kinase ERK1/2 signaling in neuronal cells, and we demonstrate here that RA induces an early stimulation of ERK1/2, which is required both for CREB phosphorylation and transcriptional activity. These results demonstrate that RA, by a nongenomic mechanism, stimulates signaling pathways that lead to phosphorylation of transcription factors, which in turn activate the transcription of genes involved in neuronal differentiation.

15 January 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
OMOlaia Martínez-Iglesias
Olaia Martínez-Iglesias
Susana Garcia-SilvaSusana Garcia-Silva
Susana Garcia-Silva
STStephan P. Tenbaum
Stephan P. Tenbaum
JRJavier Regadera
Javier Regadera
FLFernando Larcher
Fernando Larcher
AAAna Aranda
Ana Aranda
Loss of thyroid hormone receptors (TR) is a common feature in some tumors, although their role in tumor progression is currently unknown. We show here that expression of TRβ1 in hepatocarcinoma and breast cancer cells reduces tumor growth, causes partial mesenchymal-to-epithelial cell transition, and has a striking inhibitory effect on invasiveness, extravasation, and metastasis formation in mice. In cultured cells, TRβ1 abolishes anchorage-independent growth and migration, blocks responses to epidermal growth factor, insulin-like growth factor-I, and transforming growth factor β, and regulates expression of genes that play a key role in tumorigenicity and metastatic growth. The receptor disrupts the mitogenic action of growth factors by suppressing activation of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling pathways that are crucial for cell proliferation and invasiveness. Furthermore, increased aggressiveness of skin tumors is found in genetically modified mice lacking TRs, further demonstrating the role of these receptors as inhibitors of tumor progression. These results define a novel role for the thyroid hormone receptor as a metastasis suppressor gene, providing a starting point for the development of novel therapeutic strategies for the treatment of human cancer. [Cancer Res 2009;69(2):501–9]